SCHEMBL2901653

SCHEMBL2901653

C=COC(=O)c1ccccc1C(=O)c1ccc(N(CC)CC)cc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.67
▸ KMT2A Q03164 5/20 0.67
▸ MEN1 O00255 4/20 0.67
▸ L3MBTL1 Q9Y468 3/20 0.67
▸ KDM4E B2RXH2 7/20 0.53
▸ ALDH1A1 P00352 7/20 0.53
▸ GAA P10253 4/20 0.53
▸ POLB P06746 1/20 0.53
▸ MAPT P10636 10/20 0.40
▸ HPGD P15428 3/20 0.40
▸ HTT P42858 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ LMNA P02545 7/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ PGR P06401 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ AR P10275 1/20 0.39
▸ CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2319061 0.86 SMN1; SMN2 (0.72) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL2901749 0.86 SMN1; SMN2 (0.65) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL27913467 0.86 MEN1 (0.89) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL1959291 0.85 SMN1; SMN2 (0.74) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL12431397 0.84 SMN1; SMN2 (0.72) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL13301476 0.84 L3MBTL1 (0.72) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL13301466 0.83 SMN1; SMN2 (0.67) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL31512479 0.82 L3MBTL1 (0.60) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL12792825 0.82 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E
SCHEMBL12387048 0.82 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1494642-B1 Organosilicon derivatives of aminohydroxybenzophenones and their use as UV-A filters in cosmetic preparations DSM IP ASSETS BV (NL) 2010-03-10 — — EP disclosed
CN-100424076-C Organosiloxane derivatives of aminohydroxybenzophenones and their use as UV-A filters in cosmetic preparations DSM IP ASSETS BV (NL) 2008-10-08 — — CN disclosed
US-7388102-B2 Organosilicone derivatives of amino hydroxybenzophenones and their use as UV-A filters in cosmetic preparations DSM IP ASSETS B.V. (NL) 2008-06-17 — — US disclosed
US-20050255066-A1 Organosilicone derivatives of amino hydroxybenzophenones and their use as uv-a filters in cosmetic preparations DSM NUTRITIONAL PRODUCTS LTD F/K/A ROCHE VITAMINS AG (CH) 2005-11-17 — — US disclosed
CN-1646091-A Organosilicone derivatives of amino hydroxybenzophenones and their use as UV-A filters in cosmetic preparations DSM IP ASSETS BV (NL) 2005-07-27 — — CN disclosed
EP-1494642-A1 ORGANOSILICONE DERIVATIVES OF AMINO HYDROXYBENZOPHENONES AND THEIR USE AS UV-A FILTERS IN COSMETIC PREPARATIONS DSM IP Assets B.V. (NL) 2005-01-12 — — EP disclosed
WO-2003086340-A1 ORGANOSILICONE DERIVATIVES OF AMINO HYDROXYBENZOPHENONES AND THEIR USE AS UV-A FILTERS IN COSMETIC PREPARATIONS DSM IP ASSETS B.V. (NL) 2003-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050255066-A1 Organosilicone derivatives of amino hydroxybenzophenones and their use as uv-a filters in cosmetic preparations CUTA, TYR, ERCC5 SMN1; SMN2 4864/4885KMT2A 2186/4885MEN1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback